No­var­tis may still be grap­pling with Kym­ri­ah sales, but his­toric CAR-T promise still shines through 5-year da­ta

Five years af­ter No­var­tis made his­to­ry with the ap­proval of the first CAR-T, Kym­ri­ah, we’re get­ting a clear­er pic­ture of just how im­por­tant the ad­vance was for some pa­tients.

The phar­ma gi­ant may still be hav­ing trou­ble man­u­fac­tur­ing the treat­ment or reach­ing long-cher­ished goals of block­buster rev­enue, but a new study shows that its pos­i­tive ef­fects have good odds of ex­tend­ing out for years. And for many, it’s look­ing cu­ra­tive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER